论文部分内容阅读
目的探讨吉西他滨单药治疗老年晚期非小细胞肺癌的临床疗效和安全性。方法选择初治的经病理证实不能手术的老年晚期(Ⅲb～Ⅳ期)非小细胞肺癌患者42例,给予吉西单滨1000mg/m2,第1、8、15天,每4周重复。2周期后评价疗效。结果近期疗效:全组42例患者中PR12例,SD14例,PD10例,RR为29.1%,DCR为74.2%。生活质量变化:KPS评分改善33.33%(14/42),稳定45.23%(19/42),下降21.43%(9/42)。不良反应主要为骨髓抑制和消化道反应,大多数患者不良反应轻微,为Ⅰ～Ⅱ级。结论单药吉西他滨方案治疗老年晚期非小细胞肺癌安全有效。
Objective To investigate the clinical efficacy and safety of gemcitabine monotherapy in elderly patients with advanced non-small cell lung cancer. Methods Forty-two patients with non-small cell lung cancer (Ⅲb-Ⅳ stage) with pathologically confirmed inoperable were enrolled. Methods Gemcitabine 1000 mg / m 2 was given to gemcitabine at days 1, 8 and 15 and repeated every 4 weeks. After 2 cycles evaluation of efficacy. Results The short-term curative effect: The group of 42 patients in the PR12, SD14 and PD10 cases, RR was 29.1%, DCR was 74.2%. Quality of life changes: KPS score improved 33.33% (14/42), stable 45.23% (19/42), a decrease of 21.43% (9/42). Adverse reactions are mainly myelosuppression and gastrointestinal reactions, most patients with mild adverse reactions, Ⅰ ~ Ⅱ grade. Conclusion Single gemcitabine regimen is safe and effective in the treatment of elderly patients with advanced non-small cell lung cancer.